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Abstract 
Background: Prevailing data on rifampicin-resistant M. tuberculosis is essential for early management of MDR-TB. 
Therefore, this study was conducted to determine the prevalence of rifampicin-resistant Mycobacterium tuberculosis 
and associated factors among presumptive TB cases in Debre Markos Referral Hospital, Ethiopia.
Methods: A cross-sectional study was conducted from September 2014 to March 2015. Detection of M. tuberculosis 
and resistance to rifampicin was performed using Gene Xpert MTB/RIF assay. Data was collected using structured 
questionnaire by face to face interview. Logistic regression analysis was computed to determine the associated factors 
of rifampicin-resistant M. tuberculosis.
Results: A total of 505 presumptive TB patients included in the study. The prevalence of M. tuberculosis confirmed 
cases was 117 (23.2%) (95% CI 19.7–27%). It was higher among males (27.9%) than females (17.9%) (AOR: 2.17; CI 
1.35–3.49). Of the 117 M. tuberculosis confirmed cases, 12 (10.3%) (95% CI 6.0–17.1%) were resistant to rifampicin. 
Rifampicin-resistant M. tuberculosis was noticed in 7 previously treated TB patients (17.1%) and 5 treatment naive 
patients (6.7%) (AOR: 4.16; CI 1.04–16.63). The prevalence of rifampicin-resistant M. tuberculosis was 6 (9.8%) and 6 
(11.3%) in pulmonary and extra-pulmonary infections, respectively. Of the 30, MTB/HIV co-infection, 3 (10%) were 
rifampicin-resistant M. tuberculosis.
Conclusion: Rifampicin-resistant M. tuberculosis is prevalent in both pulmonary and extra-pulmonary tuberculosis 
patients. Previous treatment with anti-TB drugs was significantly associated with rifampicin resistance. Therefore, the 
use of Gene Xpert should be scaled up across the country for rapid detection and management of drug resistant M. 
tuberculosis.
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Background
Mycobacterium tuberculosis (M. tuberculosis) remains 
one of the most significant causes of death from an 
infectious agent [1]. Tuberculosis (TB) remains a major 
public health problem, accounting more than 9.4 million 
incident cases and 1.7 million deaths every year, world-
wide [2]. World Health Organization (WHO) estimates 
that 4.5 million people are co-infected with Human 
Immunodeficiency Virus (HIV) and TB globally [1, 2].
Ethiopia is one of the 22 high burden countries for 
TB. TB remains one of the leading causes of mortality 
[3]. According to the 2014 WHO report, the prevalence 
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and incidence of all forms of TB are 211 and 224/100,000 
populations, respectively [4]. TB mortality was estimated 
to be 32/100,000 populations in 2013. Among estimated 
all new TB cases, 13% are HIV co-infected [3, 4].
The emergence of drug resistance to M. tuberculo-
sis has become a significant obstacle for TB control [5]. 
The emergence and spreading of multidrug (MDR) and 
extensively (XDR) drug-resistant M. tuberculosis com-
plex (MTBC) strains poses significant challenges to TB 
control [2]. Ethiopia is one of the highest MDR-TB bur-
den countries [3]. In Ethiopia, 2.3% of new TB cases and 
17.8% of previously treated TB cases were estimated to 
have MDR [3]. Studies in Ethiopia reported 4.7–18.3% 
prevalence of rifampicin-resistant M. tuberculosis [6–10]. 
Mutations in a ‘hotspot’ region of 81  base pairs (bp) of 
rpoB gene have been found in about 96% of rifampicin 
(RMP) resistant M. tuberculosis [6].
Despite low sensitivity in detection of M. tuberculosis, 
acid-fast staining remains the main diagnostic method 
in resource-limited settings [11, 12]. Mycobacterial cul-
ture is the gold standard and the most sensitive method 
for TB diagnosis; however, its use in clinical practice is 
limited due to a slow turnaround time, biosafety require-
ments, and high cost [11, 12]. In 2011, WHO intro-
duced the wide use of Xpert MTB/RIF assay. It is a fully 
automated diagnostic molecular test using real-time 
polymerase chain reaction (PCR) technology to simul-
taneously detect M. tuberculosis and rifampicin resist-
ance mutations in the rpoB gene [13]. The Xpert assay is 
highly rapid, sensitive and specific in diagnosis of both 
pulmonary and extra pulmonary TB [8–14]. Further-
more; it was shown to be cost-effective for TB diagnosis 
compared to microscopy in low and middle income set-
tings [14].
In countries with high burden of TB, rapid detection, 
continuous surveillance and regular monitoring of drug 
resistance TB is essential for disease management and 
earlier treatment initiation. However, there is limited 
capacity to perform Xpert assay, even from patients sus-
pected of harboring drug-resistant strains with TB/HIV 
co-infection in Ethiopia. Moreover, documented data 
on the prevalence of rifampicin resistant M. tuberculo-
sis using the newly endorsed method Gene Xpert in our 
country is limited. Therefore, the aim of this study was 
to determine the prevalence and associated factors of 
rifampicin-resistant M. tuberculosis among patient’s pre-
sumptive for either TB or drug resistant TB (DR TB) in 
Debre Markos Referral Hospital.
Methods
Study design, area and period
A cross-sectional study was conducted from September 
2014 to March 2015 at Debre Markos referral Hospital 
(DMRH). DMRH has more than 147 beds offering dif-
ferent specialized services. It receives patients from the 
catchment area and referred from different areas of East 
Gojjam zone. The hospital has TB/HIV clinic as well 
as MDR-TB ward used for diagnosis and treatment of 
MDR-TB patients. The Gene Xpert MTB/RIF assay was 
conducted at DMRH tuberculosis laboratory.
Sample size
The sample size was determined using single population 
proportion formula considering 50% expected propor-
tion of rifampicin-resistant M. tuberculosis using Gene 
Xpert MTB/RIF assay, 95% confidence level and marginal 
error of 5%. Assuming 10% non-response rate, the sam-
ple size was: n = 384 + 10% = 384 + 38 = 422. However, 
505 patients provided clinical specimen adequately. Any 
patients attending in the TB clinic of DMRH presumptive 
for either TB or DR TB were the study population and 
they were enrolled consecutively.
Inclusion criteria
Patients presumptive for pulmonary or extra-pulmonary 
tuberculosis attending in the TB clinic of DMRH and vol-
unteered to participate in the study were included.
Exclusion criteria
Presumptive patients of pulmonary or extra-pulmonary 
tuberculosis who provided inadequate specimen for the 
laboratory analysis were excluded from the study.
Variables
Rifampicin-resistant M. tuberculosis was the depend-
ent variable where as demographic factors, HIV infec-
tion status, tuberculosis and treatment related conditions 
were the independent variables.
Laboratory procedures
Each eligible patient who signed written consent pro-
vided clinical specimens. From each patients presumptive 
of pulmonary TB, 4 ml of sputum sample was collected. 
In the case of presumptive extra-pulmonary TB, four 
ml of either pus, CSF, lymph node aspirate or peritoneal 
and pleural fluid samples were collected. Samples were 
immediately processed for Gene Xpert MTB/RIF assay. 
Clinical samples were diluted and decontaminated and 
Xpert MTB/RIF assay (Cepheid) was performed accord-
ing to manufacturer’s instruction. The Xpert® MTB/RIF 
purifies and concentrates M. tuberculosis bacilli from 
clinical samples. Genomic material isolated from the cap-
tured bacteria by sonication and subsequently amplifies 
the genomic DNA by polymerase chain reaction (PCR). 
Furthermore, the process identifies all the clinically rel-
evant rifampicin resistance inducing mutations in the 
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RNA polymerase beta (rpoB) gene in the M. tuberculo-
sis genome in a real time format using fluorescent probes 
called molecular beacons.
HIV testing
Testing for HIV was done according to the current 
national algorithm recommended by the Federal Ministry 
of Health of Ethiopia. Two rapid HIV tests, HIV (1 + 2) 
rapid test strip (KHB) and Stat-Pak were run sequentially. 
Samples were tested first with KHB. Positive samples 
were confirmed with Stat-Pak. Discordant results were 
resolved using a third confirmatory testing kit, HIV-1/2 
Unigold Recombinant assay. Pre and post-test HIV coun-
seling was provided for all consenting individuals.
Using a structured questionnaire data was collected by 
both face to face patient interviews and patients’ clinical 
record review. The main variables included in the study 
were age, sex, residence, reason for diagnosis, treatment 
history, and category of presumptive DR TB and site of 
tuberculosis.
Data analysis
Data were analyzed using Statistical Package for Social 
Sciences (SPSS® 20, USA). Descriptive statistics were 
used to describe the study participants in relation to rel-
evant variables. Chi-square and logistic regression analy-
sis were computed to identify the associated factors of M. 
tuberculosis and rifampicin-resistance.
Most of the variables were fitted to Chi-square test. 
Then all variables having a P value of  ≤2 in the Chi-
square test were further entered into logistic regression 
model. In the multivariate analysis, backward step wise 
logistic regression techniques were fitted and confound-
ing were controlled. Variables having P value  <0.05 in 
the multivariate analysis were taken as statistically sig-
nificant. Adjusted odds ratios with their 95% confidence 
intervals were calculated. The Hosmer and Lemshow gar-
dens-of-fit test was used to assess whether the necessary 
assumptions for the application of multiple regressions 
were fulfilled and P value >0.05 was considered as good 
fit.
Quality assurance
Both SPC and PCC internal controls used during Gene 
Xpert MTB/RIF assay. The specimen was excluded from 
the analysis if it was an invalid sample for Xpert assay or 
sample error according to Cepheid package insert. All 
procedures were done using standard operating methods.
Results
Patient characteristics
A total of 505 presumptive TB or DRTB patients par-
ticipated in the study. Of whom, 188 (37.2%) were 
presumptive DR TB. Most 265 (52.4%) were males. The 
age range of participants was 6/12  month to 92  years 
with mean age of 35.5  year. Majority (55.7%) of partici-
pants were urban dwellers. Of the total, 323 (64%) were 
presumptive for pulmonary TB while 182 (36%) were 
presumptive for extra-pulmonary TB. Four presumptive 
DRTB categories were involved in this study: 101 (52.1%) 
relapse, 62 (32%) new, 26 (13.4%) treatment failure and 
4 (2.1%) MDR contact. Prevalence of HIV was 183 (36%) 
among study participants (Table 1).
Prevalence of tuberculosis
The prevalence of M. tuberculosis confirmed TB was 117 
(23.2%) (95% CI 19.7–27%). The proportion of M. tuber-
culosis was 74 (27.9%) in males and 43 (17.9%) in females. 
The proportion of M. tuberculosis was 48 (15.1%) and 69 
(36.7%) among patients presumptive of TB and DR TB, 
respectively. From 188 presumptive DRTB cases, M. 
tuberculosis was noticed in 28 new (45.2%), 26 relapse 
(25.7%) and 14 treatment failure (53.8%) cases. M. tuber-
culosis was detected in 64 pulmonary (19.8%) and 53 
extra-pulmonary TB cases (29.1%). The rate of MTB/HIV 
co-infection was 30 (16.6%) (Table 1).
Rifampicin‑ resistant M. tuberculosis
Of the 117 M. tuberculosis cases, 12 (10.3%) were resist-
ant to rifampicin. The proportion of rifampicin-resistant 
M. tuberculosis was 7 (17.1%) among previously treated 
TB patients and 5 (6.7%) among treatment naïve patients. 
Of the 69 presumptive DR TB patients, rifampicin resist-
ant M. tuberculosis was detected in 3 new (10.7%), 5 
relapse (19.2%) and 2 treatment failure (14.3%) cases. Five 
rifampicin-resistant M. tuberculosis was noticed from all 
patients with MTB/HIV co-infection (17.9%). Rifampicin 
resistance was noticed in 6 pulmonary (9.5%) and 6 extra-
pulmonary tuberculosis cases (11.3%) (Table 2).
Associated factors
Multivariate analysis showed that M. tuberculosis infec-
tion was significantly associated with male (AOR = 2.17; 
CI 1.35–3.49), younger age (AOR  =  3.2, CI 1.23–8.21), 
previous TB therapy (AOR = 2, CI 1.03–3.96) and site of 
TB infection (AOR =  2.19, CI 1.36–3.51). On the other 
hand, rifampicin-resistant M. tuberculosis was signifi-
cantly associated with previous TB therapy (AOR = 4.16, 
CI 1.04–16.6). Male patients were 2.17 times more likely 
to have M. tuberculosis infection. TB patients who had 
previous history of TB therapy were 2 times more likely 
to have M. tuberculosis infection than treatment naïve 
patients. Moreover, TB patients who were previously 
treated by anti-TB drugs were 4.2 times more likely to 
develop rifampicin-resistant M. tuberculosis compared to 
treatment naïve patients (Tables 3, 4). 
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Table 1 Prevalence of M. tuberculosis among presumptive 
TB patients referred to  DMRH using Gene Xpert MTB/RIF 
assay, 2015
MTB M. tuberculosis, DR TB drug resistant tuberculosis








 ≤10 9 (23.7) 29 (76.3) 38 (7.5) 0.017
 11–17 7 (29.2) 17 (70.8) 24 (4.8)
 18–30 46 (34.3) 88 (65.7) 134 (26.7)
 31–40 25 (18.7) 109 (81.3) 134 (26.5)
 41–50 15 (15.1) 82 (84.5) 97 (19.2)
 51–60 9 (18) 41 (82) 50 (9.9)
 61–95 6 (21.4) 22 (79.6) 28 (5.5)
Sex
 Male 74 (27.9) 191 (72.1) 265 (52.4) 0.008
 Female 43 (17.9) 197 (82.1) 240 (47.6)
Residence
 Urban 57 (20.2) 225 (79.8) 282 (55.7) 0.007
 Rural 60 (26.9) 163 (73.1) 223 (44.3)
HIV infection
 Positive 30 (16.6) 153 (83.4) 183 (36) 0.008
 Negative 87 (26.9) 235 (73.1) 322 (64)
Reason for diagnosis
 Presumptive TB 48 (15.1) 269 (84.8) 317 (62.8) <0.001
 Presumptive DR TB 69 (36.7) 119 (63.3) 188 (37.2)
Treatment history with anti-TB drugs
 Previously treated 41 (31.6) 91 (68.9) 132 (26.2) 0.013
 Previously untreated 76 (20.4) 297 (79.6) 372 (73.8)
Presumptive DRTB
 New 28 (45.2) 34 (54.8) 62 (32) 0.024
 Relapse 26 (25.7) 75 (74.3) 101 (52.1)
 Failure 14 (92.3) 12 (7.7) 26 (13.4)
 Lost to follow-up 0 1 1 (0.5)
 MDR-contact 1 (25) 3 (75) 4 (2.1)
Site of presumptive TB
 Pulmonary 64 (19.8) 259 (80.2) 323 (64) 0.013
 Extra-pulmonary 53 (29.1) 129 (70.9) 182 (36)
Type of specimen
 Respiratory (sputum) 64 (19.8) 259 (80.2) 323 (64) 0.007
 Non-respiratory 53 (29.1) 129 (70.9) 182 (36)
Type of non-respiratory specimen
 Pus 46 (35.1) 85 (64.9) 131 (26)
 Peritoneal fluid 2 (11.8) 15 (88.2) 17 (3.4)
 Lymph node 
aspirate
1 (7.1) 13 (92.9) 14 (2.8)
 Pleural fluid 3 (23.1) 10 (76.9) 13 (2.6)
 Other 1 (14.3) 6 (83.7) 7 (1.2)
Total 117 (23.2) 388 (76.8%) 505 (100)
Table 2 Prevalence of  rifampicin-resistant M. tuberculo-
sis in each variable among  the total M. tuberculosis cases 
using Gene Xpert MTB/RIF assay, DMRH, 2015
RIF rifampicin resistant, MTB M. tuberculosis, DR TB drug resistant tuberculosis






 ≤10 2 (22.2) 7 (77.8) 0.02
 11–17 1(14.3) 6 (83.6)
 18–30 3 (6.7) 43 (93.3)
 31–40 0 25 (100)
 41–50 5 (33.3) 10 (66.7)
 51–60 0 9 (100)
 61–92 1 (16.7) 5 (83.3)
Sex
 Male 8 (11.3) 64 (88.7) 0.77
 Female 4 (8.9) 41 (91.1)
Residence
 Urban 5 (17.9) 53 (91.2) 0.76
 Rural 7 (11.9) 52 (88.1)
HIV infection
 Positive 5 (17.9) 24 (82.1) 0.17
 Negative 7 (8) 81 (92)
Reason for diagnosis
 Presumptive TB 3 (5.9) 49 (94.1) 0.22
 Presumptive DR TB 9 (13.8) 56 (86.2)
Treatment history with anti-TB drugs
 Previously treated 7 (17.1) 34 (82.9) 0.11
 Previously untreated 5 (6.7) 71 (93.3)
Presumptive DR TB
 New 3 (10.7) 25 (89.3) 0.87
 Relapse 5 (19.2) 21 (80.8)
 Failure 2 (14.3) 12 (91.7)
 MDR-contact 0 1
Site of presumptive TB
 Pulmonary 6 (9.4) 58 (90.6) 0.77
 Extra pulmonary 6 (11.3) 47 (88.7)
Specimen type
 Respiratory (sputum) 6 (9.5) 58 (90.6) 0.67
 Non-respiratory 6 (11.3) 47 (88.7)
Type of non-respiratory specimen
 Pus 4 (8.5) 43 (91.5)
 Peritoneal fluid 0 2
 Lymph node aspirate 0 1
 Pleural fluid 2 1
Total 12 (10.3) 105 (89.7)
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Discussion
In the present study, the prevalence of M. tuberculosis 
infection was similar with reports of South Africa (26%) 
[15], Northern Nigeria (23%) [16] and India (27.6%) [17]. 
However, it was lower compared to reports in Nigeria 
(31.4%) [18] and Pakistan (37%) [19]. The lower propor-
tion rate of confirmed M. tuberculosis in the present 
study compared to other studies is due to the fact that we 
included presumptive cases to identify M. tuberculosis 
while other studies included identified cases of M. tuber-
culosis to check gene Xpert technique. In contrast, it is 
higher than studies conducted in other parts of Ethiopia 
[20–22] and India [23]. The discrepancy might be due 
to difference in methods of detection of M. tuberculosis, 
community and geographical area.
In this study, the detection rate of M. tuberculosis was 
significantly higher in males than females. Likewise, 
reports from WHO [24], Ethiopia [7] and Northeast 
China [25] supports this finding. The reason for this 
might be due to social and health seeking behavior differ-
ence and higher exposure of males to outer environment, 
smoking and alcoholism [24]. The highest proportion 
of Gene Xpert positive M. tuberculosis cases were seen 
in the age group of 18–30 years. This is consistent with 
previous reports in Ethiopia [20–22, 26]. This might be 
due to more exposure to the outer environment, high 
work load and wide range of mobility of young people to 
acquire the TB bacilli as young people have.
In the present study, the proportion of M. tuberculosis 
was significantly higher in presumptive DRTB compared 
to presumptive TB patients (P < 0.001). This might be due 
to treatment failure and acquiring of resistant bacilli from 
drug resistant TB contacts. Moreover, significantly higher 
proportion of M. tuberculosis was found among patients 
treated with anti-TB drugs compared to treatment naïve 
Table 3 Multivariate analysis showing the associated pre-
dictors of M. tuberculosis in DMRH, 2015
MTB M. tuberculosis, RIF rifampicin, AOR adjusted odds ratio
a Reference category, Hosmer–Lemeshow test = 0.92, Pearson Chi-
square = 2.55, classification table = 77.4
Variables Gene expert result
M. tuberculosis AOR (95% CI) P value
Detected Not detected
Residence
 Urban 57 225 1.35 (0.86–2.13) 0.19
 Rural 60 163 a
Sex
 Male 74 191 2.17 (1.35–3.49) 0.001
 Female 43 197 a
Age, years
 ≤10 9 29 3.2 (1.23–8.21) 0.02
 11–17 7 17 3.3 (1.08–10.08) 0.036
 18–30 46 88 4.6 (1.63–12.71) 0.004
 31–40 25 109 2.76 (0.77–9.91) 0.12
 41–50 15 82 1.1 (0.46–2.70) 0.82
 51–60 9 41 1.2 (0.36–4.02) 0.77
 61–92 6 22 a
HIV infection
 Positive 30 153 1.36 (0.80–2.3) 0.25




48 269 a a
 Presumptive 
DR TB
69 119 6.83 (3.55–
13.15)
<0.001
Treatment history with anti-TB drugs
 Previously 
treated




Site of TB infection




Table 4 Multivariate analysis showing the associated pre-
dictors of  rifampicin resistant M. tuberculosis in  DMRH, 
2015
DR TB drug resistant tuberculosis, AOR adjusted odds ratio, CI confidence interval
a Reference category, Hosmer–Lemeshow test = 0.99, Pearson Chi-
square = 0.91, classification table = 89.7
Variables Resistance pattern AOR (95% CI) P value
Resistance Sensitive
Age, years
 0–10 2 7 2.3 (0.15–37.67) 0.55
 11–17 1 6 1.84 (0.08–44.6) 0.71
 18–30 3 43 0.55 (0.04–6.80) 0.64
 31–40 0 25
 41–50 5 10 4.3 (0.34–54.99) 0.23
 51–60 0 9
 61–92 1 5 a
HIV infection
 Positive 5 24 3.2 (0.69–14.96) 0.14
 Negative 7 81 a
Reason for examination
 Presumptive TB 3 49 a
 Presumptive 
DR TB
9 56 0.41 (10.04–4.21) 0.45
Treatment history with anti-TB drugs
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patients in the present study. This finding was compara-
ble to a study conducted in Zimbabwe [27].
Rifampicin-resistant M. tuberculosis is a serious health 
problem in the study population. The prevalence of 
rifampicin-resistant M. tuberculosis in this study was 
in keeping with previous studies in Nigeria [28], North 
India [29], Iran [30] and Northeast China [25]. However, 
it was higher than studies observed in Ethiopia [8, 9, 31, 
32], Kenya [33], Nigeria [34], Uganda [35] and South of 
Iraq [36]. In contrast, the proportion of rifampicin-resist-
ant M. tuberculosis was lower than reports in other parts 
of Ethiopia [7, 36] and Chile [37]. The variation could be 
due to difference in risk for HIV acquisition, exposure to 
anti-TB drugs and national TB control program. The rel-
ative higher proportion of rifampicin-resistant M. tuber-
culosis in our study could be due to the use of rifampicin 
to treat other conditions. Moreover, rifampicin has 
several adverse effects which could result in patient 
non-adherence and hence may lead to the selection of 
resistant strains.
In the present study, the proportion of rifampicin-
resistant M. tuberculosis was significantly higher among 
previously treated patients compared to treatment naive 
patients which might be due to failure from previous 
treatment and contact with drug resistant TB patients 
[26, 38–43]. However, the level of rifampicin resistance 
among previously untreated cases (6.7%) in the analysis 
close to the reported prevalence of rifampicin- resistant 
MTB (10.4%). This finding is a significant relevance in 
the current global and regional efforts to accurately and 
timely diagnose MDR-TB with the scale up of molecular 
technology like Gene Xpert MTB/RIF, providing quick 
results of rifampicin resistance as a proxy to MDR-TB.
In this study, high prevalence of rifampicin-resistant 
M. tuberculosis was detected among HIV positive cases 
which are in accordance with a study done in other part 
of Ethiopia [26] and Cambodia [44]. However, in the pre-
sent study, there was a lack of association between HIV 
infection and development of active tuberculosis as well 
as rifampicin resistance. This was consistent with the 
results of earlier studies in Ethiopia [39], Tanzania [42], 
Calabar Nigeria [35] and Brazil [45].
In the present study, the proportion of extra-pulmo-
nary tuberculosis was significantly higher compared to 
pulmonary tuberculosis; in addition the proportion of 
rifampicin-resistant M. tuberculosis was higher in non-
respiratory specimens compared to sputum. This con-
forms to a study in Cambodia [44]. This demonstrates 
that rifampicin-resistant extra-pulmonary M. tuberculo-
sis infection is a major health problem in resource-lim-
ited settings.
The major strength of this study was detection of M. 
tuberculosis and rifampicin resistance using the newly 
endorsed method Gene Xpert MTB/RIF assay from spu-
tum and non-respiratory specimens. However, the major 
limitation of this study was determination of the sample 
size using single population formula which may over-
whelm some of the associated factors. This study could 
not do the level of resistance to other anti-TB drugs and 
the finding of Gene Xpert was not compared to acid fast 
bacilli microscopy. Thus the finding of this study should 
be interpreted with these limitations.
Conclusions
Rifampicin-resistant M. tuberculosis is prevalent both in 
pulmonary and extra-pulmonary tuberculosis cases in 
the study area. Previous treatment with anti-TB drugs 
was significantly associated with rifampicin resistance. 
The strong association of rifampicin resistance with pre-
vious treatment suggests that improved monitoring of 
treatment to limit the emergence of drug resistant M. 
tuberculosis. Hence, the use of Gene Xpert should be 
scaled up across the country for rapid diagnosis, man-
agement and expanded surveillance of drug-resistant M. 
tuberculosis.
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